Asuragen enters into research agreements to develop microRNA-based diagnostic test

Links shared publicly online about this topic.

1,414
total visits

Asuragen enters into research agreements to develop microRNA-based diagnostic test

Asuragen, Inc., a leader in molecular diagnostics and RNA-based pharmacogenomics services, announced today that it has entered into research agreements with The University of Pittsburgh Medical Center, Brigham and Women's Hospital, the H. Lee Moffitt Cancer Center, Dartmouth's Hitchcock Medical Center and the University of Sherbrooke to develop a microRNA-based diagnostic test to aid the detection of pancreatic cancer from fine-needle aspirate (FNA) biopsies.

View full resource at news-medical.net

Tags: Genetic, Cancer, Pancreatic Cancer, Hospital, Women's Health, Hospitals, Brigham and Women's Hospital, University of Pittsburgh Medical Center